Expression Profile of IL-17 in lung tissues of patients with lung cancer and COPD and clinical significance

Abstract

The purpose of this experiment to analyze the expression and clinical significance of interleukin-17 (IL-17) in lung tissue of lung cancer patients with chronic obstructive pulmonary disease (COPD). For this aim, 68 patients with lung cancer and chronic obstructive pulmonary disease who were admitted to our hospital from February 2020 to February 2022 were selected as the research objects of the study group. The specimens were fresh lung tissue obtained after lobectomy; In addition, 54 healthy subjects were selected as the control group during the same period, and fresh lung tissue obtained by minimally invasive lung volume reduction was selected as the sample. The clinical baseline data of the two groups were observed and compared. The mean alveolar area, small airway inflammation score and Ma tube wall thickness were measured. The expression of IL-17 was detected by immunohistochemistry. Results showed that gender, average age and average body mass index of the two groups (P > 0.05); At present, the proportion of smokers, pulmonary artery systolic pressure, PaCO2 level and CRP level in the study group are high, PaO2 level, FEV1% predicted value, FEV1 / FVC and FIB level are low, and the number of acute exacerbations in the past year is high (P > 0.05). In the study group, the average alveolar area, the thickness of the Ma tube wall, the lymphocyte infiltration score of the tracheal wall and the total pathological score of the small airway were higher (P > 0.05). The expression of IL-17 in the airway wall and lung parenchyma was higher in the study group (P > 0.05). IL-17 expression in lung tissue of lung cancer patients with COPD was positively correlated with body mass index, and negatively correlated with CRP, FIB, FEV1% predicted value and the number of acute exacerbations in the past year; CRP and the number of acute exacerbations in the past year were independent variables and independent influencing factors of IL-17 expression (P < 0.05). In conclusion, IL-17 is highly expressed in the lung tissues of patients with lung cancer and COPD, which may play an important role in the occurrence and development of the disease.